Iron (ferric citrate) proves to be effectivein reducing phosphorous levels for Renal Patients on dialysis.

FDA approved Ferric citrate for lowering of serum phosphorus levels in patients of chronic kidney disease on dialysis.

Chronic Kidney disease (CKD) in which kidneys cannot flush out the waste. It results in high levels of phosphate in the blood, a condition known as hyperphosphatemia which is risk for heart and bone disease and may lead to death. The blood loss during dialysis may lead to iron deficiency.

 In US Ferric citrate is used in for the treatment for iron deficiency anaemia in patients with CKD. Ferric citrate increases the iron in the blood. Physician must need to evaluate iron levels in dialysis patients and may need to reduce or stop IV iron therapy.

Ferric citrate is very favorable for kidney patients on dialysis as it is reducing the phosphorus levels and increasing iron levels. Thus it reduces the cost for chronic kidney patients on dialysis by treating Anemia and lowers phosphate.

Ferric citrate is contraindicated in patients with hemochromatosis in which there is excessive amount of iron in the body. Keep away from children as it contains iron. It can lead to poisoning in children under age of 6.

Adverse effects: diarrhea, nausea, constipation, vomiting, cough. Refer HealthEver for more information on Ferric citrate.